Deal Watch: Ionis Out-Licenses Pair Of Generation 2.5 Antisense Candidates
Janssen and French biotech Dynacure take licenses to antisense candidates arising from Ionis’ Generation 2.5 technology. Merck and Cue sign autoimmune partnership, while Bayer and PeptiDream ink discovery pact.
You may also be interested in...
France’s fledgling biotech Dynacure has pulled together a series C funding round to support its ongoing Phase I/II study of an antisense molecule for an ultrarare myopathy.
Originated from Tokyo University, drug discovery firm PeptiDream recently competes pre-clinical study for its anti-flu peptide PD-001, after signing 17 deals with large drug makers in 11 years. The company's CEO Patrick Reid outlines to Scrip prospects of peptide-drug conjugates (PDCs) and discovery strategy.
As the Chinese government looks to promote 'made in China' innovation, AstraZeneca has established a joint venture called Dizal Pharmaceuticals in tandem with a well-financed and influential local fund.